Curated News
By: NewsRamp Editorial Staff
October 15, 2026
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
TLDR
- Helus Pharma appointed Dr. Suresh Durgam to its board, adding proven CNS drug development expertise to advance its late-stage pipeline.
- Helus Pharma named Dr. Suresh Durgam to its board, leveraging his 20 years of CNS experience and FDA approval track record to guide HLP003 and HLP004.
- Helus Pharma appointed Dr. Suresh Durgam to its board, advancing novel serotonergic agonists that aim to heal minds and improve mental health treatments.
- Helus Pharma added Dr. Suresh Durgam to its board, bringing expertise from CAPLYTA approvals to its psychedelic-inspired antidepressant pipeline.
Impact - Why it Matters
This news matters because the appointment of Dr. Suresh Durgam, a seasoned CNS drug development expert with a proven track record at Intra-Cellular Therapies, significantly strengthens Helus Pharma's leadership as it advances its pipeline of novel serotonergic agonists. With HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder, Helus Pharma is positioned to potentially bring new, more effective treatments to millions suffering from mental health conditions. Durgam's experience in securing FDA approvals for CAPLYTA across multiple indications will be invaluable in navigating the regulatory landscape and accelerating the path to commercialization. For investors, this strategic addition to the board could enhance the company's credibility and drive value, while for patients, it signals hope for innovative therapies that address unmet needs in depression and anxiety.
Summary
Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), has appointed Suresh Durgam, M.D., to its board of directors, pending approval by Cboe Canada. Durgam, who previously served on the company's scientific advisory board, brings over 20 years of experience in central nervous system (CNS) drug development, clinical research, and regulatory strategy. His most recent role was executive vice president and chief medical officer at Intra-Cellular Therapies, where he was instrumental in securing U.S. Food and Drug Administration approvals for CAPLYTA(R) across multiple indications, including schizophrenia, bipolar depression, and major depressive disorder. This appointment is expected to bolster Helus Pharma as it advances its CNS pipeline through late-stage development toward potential commercialization.
Helus Pharma(TM), the commercial operating name of Cybin Inc., founded in 2019, is committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to improve the treatment landscape through NSAs that provide durable improvements in mental health. Currently, the company is developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the FDA, and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland.
For more information, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. Helus Pharma(TM) is a trademark of Cybin Corp. The latest news and updates relating to HELP are available in the company's newsroom. This article has been disseminated on behalf of Helus Pharma and may include paid advertising. MissionIR, a specialized communications platform, is powered by IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
